Huseyin Naci

15PUBLICATIONS
34CO-AUTHORS
Behavioural epidemiologyPharmacogenomicsCancer diagnosisMolecular targetsPacific Peoples midwifery and paediatrics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Aug 13, 2026
Factors influencing FDA drug approval decisions beyond clinical trial evidence: a scoping review.

|Jul 28, 2026
Completion and outcomes of postmarketing requirements and commitments issued by the US Food and Drug Administration for new drugs, 2016-24: cross sectional evaluation of postmarketing studies.

|Jul 26, 2026
Navigating the Prescription Drug Information System.

|Dec 23, 2025
Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation.

Huseyin Naci, Mahnum Shahzad, Peter Murphy

|Dec 17, 2025
Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study.

Rylee McGonigle, Huseyin Naci, Maximilian Siebert

|Mar 29, 2023
Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe.

Courtney Davis, Anita K Wagner, Maximilian Salcher-Konrad

Pageof 3

Frequent Collaborators

3 joint publications

Maximilian Siebert

3 joint publications

Anita K Wagner

2 joint publications

Florence T Bourgeois

2 joint publications

Sanjay Basu